CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 333 enrolled
Drug / intervention
Leuprorelin acetatedrug
Likely dose
Leuprorelin acetate 22.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03209492
NCT03209492N/ACompleted
CompareCT.gov

Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

Takeda·observational·Posted Jul 6, 2017·Updated Apr 11, 2019

In Brief

An observational study evaluating Leuprorelin acetate for Prostate Cancer. Completed, enrolled 333 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 6, 2017
Enrollment StartApr 1, 2016
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.0 years ago

Interventions

Leuprorelin acetatedrug

Leuplin PRO for Injection Kit 22.5 mg